2026 ICD-10-CM Diagnosis Code C75.1Malignant neoplasm of pituitary gland

ICD-10-CM Codes›C00–D49›C73-C75›C75

ICD-10-CM C75.1
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

C75.1 is a billable ICD-10-CM diagnosis code for malignant neoplasm of pituitary gland. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 643 through 645. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Endocrine system cancers - pituitary gland.

Code Identity

ICD-10-CM Code
C75.1
Billable Status
Yes — Valid for Submission
Code Describes
Malignant neoplasm of pituitary gland
Short Description
Malignant neoplasm of pituitary gland
Same as the full description in the CMS dataset.
Parent Code
C75
Malignant neoplasm of other endocrine glands and related structures

Code Classification

ChapterC00–D49Neoplasms
SectionC73-C75Malignant neoplasms of thyroid and other endocrine glands
CategoryC75Malignant neoplasm of other endocrine glands and related structures
This CodeC75.1Malignant neoplasm of pituitary gland

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Adenocarcinoma of pituitary gland
  • Carcinoma of brain
  • Ependymoma of cerebrum
  • Low grade glioma of cerebrum
  • Malignant neoplasm of craniopharyngeal duct
  • Malignant neoplasm of hypothalamus
  • Malignant neoplasm of pituitary and hypothalamus
  • Malignant neoplasm of pituitary gland
  • Malignant neoplasm of pituitary gland and craniopharyngeal duct
  • Malignant pituitary blastoma
  • Mass of neurohypophysis
  • Neoplasm of craniopharyngeal duct
  • Neoplasm of hypothalamus
  • Neoplasm of uncertain behavior of endocrine glands and nervous system
  • Neoplasm of uncertain behavior of pituitary gland
  • Pituitary carcinoma
  • Primary adenocarcinoma of pituitary gland
  • Primary malignant neoplasm of pituitary gland
  • Primary pituitary carcinoma
  • Sellar ependymoma of posterior pituitary gland

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Adenocarcinoma
      • acidophil
        • unspecified site
    • Adenocarcinoma
      • basophil
        • unspecified site
    • Adenocarcinoma
      • chromophobe
        • unspecified site
    • Adenocarcinoma
      • eosinophil
        • unspecified site
    • Adenocarcinoma
      • mucoid
        • cell
          • unspecified site
    • Carcinoma(malignant)
      • acidophil
        • unspecified site
    • Carcinoma(malignant)
      • acidophil-basophil, mixed
        • unspecified site
    • Carcinoma(malignant)
      • basophil
        • unspecified site
    • Carcinoma(malignant)
      • basophil-acidophil, mixed
        • unspecified site
    • Carcinoma(malignant)
      • chromophobe
        • unspecified site
    • Carcinoma(malignant)
      • eosinophil
        • unspecified site
    • Carcinoma(malignant)
      • mucoid
        • cell
          • unspecified site

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO055
Endocrine system cancers - pituitary gland
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Empty Sella Syndrome

    a condition when the sella turcica is not filled with pituitary tissue. the pituitary gland is either compressed, atrophied, or removed. there are two types: (1) primary empty sella is due a defect in the sella diaphragm leading to arachnoid herniation into the sellar space; (2) secondary empty sella is associated with the removal or treatment of pituitary neoplasms.

  • Sella Turcica

    a bony prominence situated on the upper surface of the body of the sphenoid bone. it houses the pituitary gland.

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary		Malig.
Secondary		Ca
in situ		BenignUncertainUnspec.
fossa (of) › pituitaryC75.1C79.89D09.3D35.2D44.3D49.7
hypophysisC75.1C79.89D09.3D35.2D44.3D49.7
intrasellarC75.1C79.89D09.3D35.2D44.3D49.7
pituitary (body) (fossa) (gland) (lobe)C75.1C79.89D09.3D35.2D44.3D49.7
Rathke's pouchC75.1C79.89D09.3D35.2D44.3D49.7
sella turcicaC75.1C79.89D09.3D35.2D44.3D49.7

Patient EducationClinical

Pituitary Tumors

Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C75.1 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
194.3 Malig neo pituitary
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About C75.1Overview

Is C75.1 a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of pituitary gland on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does C75.1 group to?

When malignant neoplasm of pituitary gland is the principal diagnosis on an inpatient stay, it groups to MS-DRG 643, 644, 645, with relative weights from 0.7683 to 1.6461 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of C75.1?

Under the General Equivalence Mappings, malignant neoplasm of pituitary gland converts to ICD-9-CM 194.3 (malig neo pituitary). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.